Clinical Trial

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and chronic myelomonocytic leukemia. Ropeginterferon alfa-2b is a form of interferon. Interferons are a type of signaling protein normally produced by the body as part of the immune response. Interferons interfere with the division of cancer cells and can slow cancer cell growth. Ropeginterferon alfa-2b is a long-acting form of a type of interferon called interferon alfa-2b. In the body, ropeginterferon alfa-2b causes the production of proteins that modulate the immune system and have anticancer effects.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2031-03-30 -> 2031-09-30 2026-05-07
minor Completion pushed: 2032-03-30 -> 2032-09-30 2026-05-07
Trial Details
NCT Number NCT07468916
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: PharmaEssentia
Conditions Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Enrollment 35 participants
Start Date 2026-09-29
Primary Completion 2031-09-30 (estimated)
Study Completion 2032-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-06